Terbinal

Quick links to important sections

Terbinal

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbinal

Quick Facts

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Tablets (Oral) and Topical preparations
Pharmacological Class Allylamine Antifungal Agent
General Purpose To eliminate fungal organisms
Origin Synthetic Compound

Terbinal: An Allylamine Antifungal Agent

Terbinal is a synthetic pharmaceutical preparation containing the active ingredient Terbinafine Hydrochloride. It is scientifically classified as an Antifungal Agent, belonging specifically to the Allylamine Antimycotic group. This classification defines its specialized action against various fungal organisms, particularly the dermatophytes that commonly affect skin and nails. This medication functions as a single-active-ingredient product, relying entirely on the unique chemical action of Terbinafine.

Composition and Forms: Systemic versus Topical Use

The medicine is produced in two fundamental formats, which determine the route of administration: tablets for oral (systemic) ingestion, and a range of topical preparations such as cream, solution, or spray, for local application. The composition consists of the active Terbinafine and necessary inactive bases; for instance, the oral tablets include excipients like microcrystalline cellulose. This dual-form availability is crucial because the choice between systemic and topical administration dictates the approach to clearing the fungal source, ensuring targeted delivery, whether to the surface of the skin or for deeper-seated infections.

How Terbinafine Differs from Other Antifungal Classes

The core therapeutic value of Terbinafine is its potent fungicidal action—meaning it actively causes the death of the fungal cell, a process considered more definitive than the fungistatic effect (slowing growth) characteristic of some older antifungal classes. This mechanism involves the highly specific disruption of the fungal cell membrane integrity. The medicine maintains a high affinity for keratinous tissues, which contributes to its general efficacy in treating infections in skin and nails, providing its key general purpose: to achieve the necessary and complete eradication of the fungal source.

What side effects are possible with Terbinal?

Possible Side Effects and Safety Information

The official safety profile for Terbinal (Terbinafine) organizes potential adverse reactions by frequency and the body system affected, strictly according to regulatory classification standards.


Frequency-Classified Adverse Reactions (Oral)

Classification Examples of Officially Listed Effects
Common (≥ 1/100 to < 1/10) Headache, diarrhea, dyspepsia, nausea, abdominal pain, rash, pruritus (itching), and liver enzyme abnormalities.
Rare (≥ 1/10,000 to < 1/1,000) Hepatotoxicity/liver failure, dizziness, paresthesia, and visual disturbance.
Very Rare (< 1/10,000) Severe skin reactions (e.g., Toxic Epidermal Necrolysis), and blood dyscrasias (e.g., neutropenia).
Frequency Not Known Loss of taste (ageusia), loss of smell (anosmia), and depressive symptoms.

Serious Adverse Reactions and Systemic Safety

Regulatory documents explicitly list Serious Adverse Reactions, including the potential for hepatotoxicity and liver failure, severe skin reactions (such as DRESS syndrome), and rare blood disorders (e.g., severe neutropenia). These effects primarily involve the Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, and Blood and Lymphatic System Disorders systems.

Specific time-related patterns are noted: taste and smell disturbances may be prolonged or, in rare cases, permanent, while serious skin reactions may develop weeks to months after starting treatment. The official label establishes high-level Safety Restrictions:

  • Contraindication: Oral Terbinal is contraindicated in individuals with chronic or active hepatic disease.
  • Monitoring Note: Measurement of serum transaminases (liver enzymes) is advised prior to initiating oral therapy.

For Population-Specific Safety, the medicine is noted to be excreted into breast milk, and use is generally restricted during pregnancy unless clearly necessary.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Terbinal (Terbinafine) overdose documents the known clinical manifestations and specifies the required emergency actions. An overdose, which has been reported following exposures up to 5 grams in some cases, may present with a defined cluster of symptoms. These documented signs include gastrointestinal effects such as nausea, vomiting, and abdominal pain. Central nervous system effects like dizziness and headache may also occur, along with dermatological signs such as rash and frequent urination.

Due to the severity potential of any drug overdose, official government labeling explicitly mandates that any individual with known or suspected overdose must seek immediate medical attention or contact emergency services. This urgent need for professional care is necessary because no specific antidote is known for Terbinal.

The procedural management described in regulatory documents is supportive. Treatment aims to eliminate the active ingredient, often starting with the administration of activated charcoal to reduce further systemic absorption. Following this, the focus shifts entirely to providing symptomatic and supportive treatment to manage the clinical manifestations that arise. Professional monitoring and observation are typically required to oversee the elimination process. No specific population-based differences in acute overdose presentation are detailed in the official labeling.

Therapeutic Uses of Terbinal

What Terbinal Treats: Main Uses and Benefits

Terbinal (Terbinafine) is commonly used to address the source of persistent symptoms related to fungal organisms, focusing on managing conditions where functional stability may be affected. Its application is relevant across several specific fungal conditions.


The medication is applied across therapeutic domains involving distressing symptoms from infections like onychomycosis (nail fungus), Tinea pedis (athlete's foot), Tinea cruris (jock itch), Tinea corporis (ringworm of the body), and Tinea capitis (scalp ringworm). It is relevant for easing the characteristic red, scaly rashes, as well as the thickening and discoloration of nails. This therapy contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Terbinal is commonly used during phases when symptoms become more noticeable, particularly for conditions presenting with systemic or localized discomfort. Its use may assist with managing symptoms related to inflammatory or irritative states, supporting the return to functional stability in affected areas.

Quick Fact: Supportive Management for Fungal Symptoms

Context Benefit Provided
Nail Dystrophy Assists with maintaining functional stability and may assist with nail regrowth
Skin Scaling & Redness Helps maintain a sense of stability
Pruritus (Itching) Is applied in addressing symptoms that interfere with comfort

Regulatory References

  1. MedlinePlus Drug Information on Terbinafine

Eligibility and Restrictions for Use

Terbinal (terbinafine) tablets are subject to strict eligibility rules outlined in official regulatory documents, primarily due to the risk of serious side effects. Determining eligibility focuses on the patient's existing health status, particularly liver and kidney function.

Contraindicated Populations

Terbinal is contraindicated and must not be used by two main patient groups:

  • Individuals with a known hypersensitivity or allergic reaction history to terbinafine.
  • Patients with active or chronic liver disease due to the risk of severe hepatotoxicity, including liver failure. Pretreatment liver function tests are required for all patients.

Conditional and Restricted Use

Population/Condition Eligibility Status
Renal Function Not Recommended in patients with impaired renal function (creatinine clearance <50 mL/min) as use has not been adequately studied.
Pregnancy Not Recommended. Use is limited to cases where the benefits clearly outweigh the risks, as non-urgent treatment can often be delayed.
Breastfeeding Not Recommended. Terbinafine is excreted into human breast milk.
Pediatric Use Approved for children 4 years of age and older for tinea capitis (scalp ringworm), with dosage based on body weight. Use in younger children or for other indications is generally not established.

What should I know about interactions with other medicines?

Terbinal (terbinafine) has known interactions primarily rooted in its effect on certain Cytochrome P450 (CYP) enzymes in the liver. These interactions may result in changes to the blood levels of either Terbinal or the co-administered medication, requiring clinical monitoring and potential dose adjustment.

Impact on Co-administered Medicines

Terbinal is an inhibitor of the CYP450 2D6 (CYP2D6) isozyme, which can lead to increased systemic exposure of drugs primarily metabolized by this enzyme. Interacting medicine categories include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, and Class 1C antiarrhythmics (such as flecainide and propafenone). For example, coadministration with desipramine can cause a substantial increase in the exposure of desipramine. Careful monitoring and a reduction in the dose of the CYP2D6-metabolized drug may be required. The CYP2D6-inhibitory effect of Terbinal has been shown to persist for several weeks after stopping treatment.

Impact on Terbinal Exposure

Other drugs can alter the clearance of Terbinal. Strong inhibitors of CYP450 2C9 and CYP3A4 enzymes, such as fluconazole, significantly increase Terbinal’s systemic exposure. Conversely, strong inducers of metabolism like rifampin are documented to increase Terbinal clearance, potentially reducing its effectiveness. Additionally, Terbinal has been shown to decrease the clearance of caffeine.

Mechanism of Action

How Terbinal Works

Targeted Inhibition of Fungal Squalene Epoxidase

The mechanism of Terbinal (Terbinafine) begins with the highly specific, non-competitive inhibition of the fungal enzyme squalene epoxidase (also known as squalene monooxygenase). This enzyme is the primary biological target, and its blockade is the molecular event that initiates the entire sequence of the drug's action, defining the selective nature of the effect. Inhibition of this key fungal enzyme halts a vital metabolic function, leading to the fungal cell's destruction.

Dual Disruption Leading to Fungicidal Action

This molecular blockade results in a destructive dual disruption of the fungal cell's structure and chemistry: a severe deficiency of ergosterol (the necessary structural sterol) and the toxic accumulation of the precursor molecule, squalene. This combined assault significantly compromises the cell membrane's integrity, leading to immediate lysis and death of the fungal cell, which is the core physiological change produced by the mechanism.

Mechanism Selectivity in Keratinous Tissues

The mechanism is supported by the drug's high affinity for keratinous tissues (skin, hair, and nails), which facilitates accumulation at the site of fungal residence. This mechanism is primarily effective in driving a definitive fungicidal effect against dermatophyte fungi, though its potency may be constrained in certain other non-dermatophyte species, where the action may be fungistatic rather than fungicidal.

Dosage and Administration Information

How to Use Terbinal

Terbinal (Terbinafine) administration follows standard protocols regarding routes, dosages, and duration patterns. The medicine is administered via oral intake for systemic effects, primarily using 250 mg tablets, or through topical application via 1% cream, solution, or spray.


Administration Protocols

Systemic treatment involves a 250 mg dose taken once daily for adults. The course duration depends on the infection site; for instance, fingernail onychomycosis typically requires a 6 week duration, while toenail onychomycosis requires 12 weeks. Topical preparations are generally applied once or twice daily for shorter periods, such as 1 to 2 weeks for skin infections.


Preparation and Context

Parameter Instruction Summary
Oral Tablets Intake May be swallowed whole, with or without food.
Oral Granules Intake Must be sprinkled on a spoonful of soft, non-acidic food and swallowed immediately without chewing.
Pediatric Dosing Utilizes a specific weight-based, tiered regimen for certain indications, such as tinea capitis.

Procedural Consistency

If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if the time for the next dose is near (e.g., within less than 4 hours), the missed dose should be skipped. These protocols provide a consistent, standardized approach to administration, specifying the route, frequency, and duration patterns required for use.

Recent Clinical Evidence

Terbinal: Recent Clinical Evidence

The research evidence for Terbinal is primarily based on numerous Randomized Controlled Trials (RCTs) and large meta-analyses. The most extensive data focuses on fungal nail infection (onychomycosis). These trials, conducted mainly in adults, examined two key outcomes: mycological cure (confirming the absence of fungus) and tracking the physical changes of the nail over extended follow-up periods, often a year or more, necessary for new nail growth.


For common fungal skin infections, such as athlete's foot (Tinea pedis), the research includes RCTs evaluating both oral and topical formulations. These studies explored short-term changes in fungal status and symptoms, including scaling and itching.


The evidence base for scalp ringworm (Tinea capitis) is smaller and consists of specialized RCTs and Pharmacokinetic (PK) studies conducted in the pediatric population (children). These studies evaluated mycological cure and tracked changes in scalp lesion appearance, noting that observed outcomes may vary depending on the causative fungal species.


Research has explored Terbinal in special groups like patients with diabetes and specific older adult cohorts. However, a consistent limitation across all indications is the lack of long-term data over multiple years regarding recurrence rates. Furthermore, existing studies provide limited insight into populations often excluded from large trials, such as those with significant pre-existing kidney or liver conditions. Research is ongoing to examine treatment regimens.

Frequently Asked Questions (FAQ)

Common questions about Terbinal (FAQ)


Q: What is the main reason Terbinal is prescribed?

A: Terbinal (Terbinafine) is an antifungal medicine. According to official product information, the primary approved use for the oral tablets is the treatment of onychomycosis, which is a fungal infection of the fingernails or toenails.


Q: Can Terbinal be used for different types of fungal infections, or just one?

A: The oral tablet form is approved to treat fungal infections affecting the fingernails and toenails. It is also sometimes used in cases of severe fungal skin infections, such as certain forms of ringworm (tinea corporis and tinea cruris). Topical (cream/spray) forms address a wider range of superficial infections.


Q: Is Terbinal related to other antifungal medicines?

A: Official sources classify Terbinal (Terbinafine) as belonging to a specific group of medications known as allylamine antifungals. It is important to note that this medicine is an antifungal and is not classified as a steroid or an antibiotic.


Q: Why is Terbinal sometimes prescribed for a long time?

A: The duration of treatment, which can be up to 12 weeks for toenails, is due to the nature of the infection. The medicine clears the fungus from the area, but the visible result depends on the time it takes for the new, healthy nail to grow out. Therefore, official guidelines typically recommend completing the full prescribed period.


Q: Do you have to finish the full course of Terbinal, even if you feel better?

A: Official guidance often emphasizes completing the full prescribed treatment course. Stopping the medicine early, even if symptoms appear to be gone, may increase the chance that the fungal infection could return or become more difficult to treat.


Q: How long does it usually take to see results from Terbinal?

A: Visible results are often delayed because the infected nail must grow out completely after the medicine has cleared the fungus. For nail infections, the full effect is typically observed several months after the treatment course itself has been completed.


Q: Are there any foods or drinks I need to avoid while on Terbinal?

A: It is officially recommended to avoid or severely limit the consumption of alcohol during the course of treatment. This warning is in place because both Terbinal and alcohol are known to affect the liver.


Q: Can Terbinal cause changes to my liver test results?

A: Official product information indicates that abnormal liver function tests are a reported side effect of oral Terbinal. In rare cases, severe liver damage, including liver failure requiring transplant, has occurred in individuals both with and without pre-existing liver conditions.


Q: Why is liver function sometimes checked before starting Terbinal?

A: Liver function is checked using blood tests before treatment begins because pre-existing active or chronic liver disease is a contraindication (a reason the drug should not be used). This screening helps to identify pre-existing conditions that increase the risk of serious liver injury, which is a known potential side effect.


Q: What are the most commonly reported side effects of Terbinal?

A: Common adverse events reported in clinical trials and post-marketing experience include headache, diarrhea, skin rash, and gastrointestinal symptoms like upset stomach and nausea. Abnormal liver function tests are also commonly reported.


Q: Is it common to have stomach upset when first starting Terbinal?

A: Gastrointestinal issues are reported among the common adverse effects when taking oral Terbinal. These may include diarrhea, nausea, abdominal pain, and general upset stomach (dyspepsia).


Q: Is it true that Terbinal can change my sense of taste?

A: Changes in the sense of taste, including partial or complete taste loss (dysgeusia), have been reported in official warnings. This disturbance can be severe and, in rare instances, may be prolonged or permanent after the medication is stopped. Official product information notes that the medicine is typically discontinued if this occurs.


Q: Does Terbinal cause long-term side effects?

A: While most side effects resolve after stopping the medicine, changes in the sense of taste or smell have been reported to be prolonged (lasting over a year) or, in rare cases, permanent. Depressive symptoms have also been reported.


Q: Are there any specific safety warnings I should know about before taking Terbinal?

A: Regulatory documents list several warnings, including the risks of liver failure and severe skin reactions like Stevens-Johnson Syndrome (SJS). Potential changes in the sense of taste, smell, and the development of depressive symptoms are also noted.


Q: What should I do if a side effect seems serious?

A: Official warnings describe serious adverse effects that may warrant immediate attention from a healthcare provider. These include symptoms related to liver injury (such as jaundice, dark urine, or persistent nausea) or signs of a severe skin reaction (such as blistering, fever, or a widespread rash).


Q: Are there any medical conditions that make it unsafe to use Terbinal?

A: Terbinal is contraindicated (should not be used) in patients with a known history of chronic or active liver disease. It should also be avoided by individuals who have experienced an allergic reaction to oral Terbinal.


Q: How does Terbinal use relate to underlying immune system issues?

A: Caution is advised for patients with a weak immune system. In some cases, official reports mention the development of severe neutropenia (a low white blood cell count), which is generally reversible upon stopping the medication.


Q: Can people with kidney problems use Terbinal?

A: Official product information does not recommend the use of oral Terbinal for patients who have moderate to severe renal impairment (significantly reduced kidney function).


Q: Is Terbinal suitable for children?

A: Yes, oral forms of the medicine have established weight-based dosing regimens for children aged 4 years and older for specific conditions, most commonly tinea capitis (fungal infection of the scalp). Safety and efficacy have not been established in children younger than 4 years old.


Q: Can elderly patients use Terbinal safely?

A: The use of Terbinal in elderly patients requires caution. This is because older adults are more likely to have age-related issues with liver, kidney, or heart function, which may impact how the medicine is processed by the body.


Q: What does the research say about Terbinal's use in different age groups?

A: Studies and labeling indicate that while treatment regimens exist for certain children, elderly patients may be at a higher risk for adverse events. This is due to a greater likelihood of underlying conditions like liver or kidney problems that can affect how the drug is cleared.


Q: Is Terbinal safe to use during pregnancy?

A: Based on limited clinical experience, oral Terbinal is not generally recommended for use during pregnancy. Patients who are pregnant or planning pregnancy should consult with their healthcare provider to weigh the potential risks and benefits.


Q: Is Terbinal safe to use while breastfeeding?

A: Official information indicates that Terbinal passes into breast milk. Therefore, treatment with the oral tablets is generally not recommended for mothers who are currently breastfeeding.


Q: Are there any known issues with Terbinal and sun exposure?

A: The medicine can cause photosensitivity, meaning it can increase your skin's sensitivity to sunlight. Official warnings note that excessive sun exposure and the use of tanning beds should be avoided while taking Terbinal.


Q: Does Terbinal affect sleep or cause insomnia?

A: Official product information lists sleep problems, including insomnia (difficulty sleeping) and changes in sleep patterns, as possible adverse reactions reported during treatment.


Q: Can Terbinal affect my ability to drive or operate machinery?

A: Although not a direct warning, if a patient experiences side effects such as dizziness or lightheadedness (which are known adverse events), caution may be necessary, and driving or operating heavy machinery may need to be avoided.


Q: What kind of monitoring is typically done while taking Terbinal?

A: Monitoring is important due to the risk of liver injury. It is recommended to check serum transaminases (liver enzymes) before starting the drug, and periodic monitoring of liver function tests is generally recommended during treatment.


Q: How quickly is Terbinal cleared from the body?

A: Terbinal has a long-lasting presence in the body's tissues. The effective half-life (the time it takes for the concentration to halve) in the blood is about 36 hours, but the terminal half-life, reflecting clearance from skin and fat, can range from 200 to 400 hours.


Q: Is there a list of all potential interactions for Terbinal?

A: Terbinal is known to affect certain liver enzymes involved in drug processing, leading to the potential for interactions with many other medications. While official documents list many specific interactions, official sources recommend reviewing all concomitant medicines and supplements with a healthcare provider.


Q: What were the main findings of the pivotal clinical trials for Terbinal?

A: Clinical trials for the oral tablets established their efficacy against toenail infections by comparing treatment to a placebo (no treatment). Studies generally showed that a 12-week course was effective for the specific indication of onychomycosis.


Q: Are there different brand names for Terbinal?

A: Yes, the medication known by the generic name Terbinafine is marketed under various brand names globally. In the United States, the most widely recognized brand name is Lamisil.


Q: What are the general guidelines for storing Terbinal medication?

A: The medication should be stored in a dry place at room temperature, typically below 25 C (77 F). It should be kept protected from light and moisture, away from the reach of children.


Q: What does the term 'contraindication' mean for Terbinal?

A: A contraindication is a condition or factor that makes a specific treatment or procedure inadvisable due to the potential harm it could cause. For Terbinal, an example is active liver disease, meaning the drug should not be used in this patient population.


Q: Is Terbinal available over the counter, or is it prescription-only?

A: The oral tablet form of Terbinal is generally a prescription-only medication. However, some lower-strength topical forms, such as creams and sprays for minor skin infections, may be available over-the-counter.

How should Terbinal be stored and disposed of?

How to Store and Dispose of Terbinal?

Official regulatory information strictly defines the necessary storage environment and disposal protocols for Terbinal (Terbinafine) to maintain product stability and safety.

Requirement Oral Tablets (Systemic Use) Topical Cream (Local Use)
Temperature Range Store at Controlled Room Temperature (20 C to 25 C) [NIH DailyMed/FDA]. Store below 30 C [SmPC]. Do not freeze. [SmPC]
Container & Protection Keep in a tightly closed container and store in the original package to protect from light [NIH DailyMed/SmPC]. Keep the tube tightly closed and store in the original container.
In-Use Stability Stability is tied to the expiration date. Shelf life after first opening is 28 days [SmPC].
Disposal Rule Any unused or expired product must be disposed of in accordance with local requirements [SmPC]. Return expired or unused medicine to a pharmacist for disposal.

All forms of this medication must be kept out of the sight and reach of children [NIH DailyMed].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbinal found in:

A-Z Index: